Can Hydrochlorothiazide Cause Elevated Liver Enzymes?
Yes, hydrochlorothiazide can cause elevated liver enzymes, though this is a rare adverse effect. While the FDA label for hydrochlorothiazide does not specifically list hepatotoxicity as a common side effect, case reports document drug-induced liver injury (DILI) from this medication 1, 2.
Evidence for Hepatotoxicity
The evidence base consists primarily of case reports rather than large-scale studies:
Case documentation: Published cases describe hydrochlorothiazide-induced hepatotoxicity presenting as jaundice with elevated transaminases and bilirubin. In one case, an 86-year-old woman developed jaundice after taking hydrochlorothiazide, with liver biopsy confirming drug-induced hepatitis. Clinical and biochemical manifestations resolved after discontinuation 1.
Pattern of injury: Reported cases show hepato-cholestatic injury patterns, with both hepatocellular and cholestatic features 2.
Incidence: This is considered a rare adverse effect. The FDA label focuses on electrolyte disturbances (hypokalemia, hyponatremia, hypochloremia) as the primary metabolic toxicities, not hepatotoxicity 3.
Clinical Context
Important distinction: In the PolyIran-Liver trial involving 1,508 participants with presumed non-alcoholic steatohepatitis (pNASH), a polypill containing hydrochlorothiazide (along with aspirin, atorvastatin, and valsartan) showed no change in liver enzymes over 5 years. Among those with pNASH specifically, there was actually a significant decrease in liver enzymes after 60 months (-12.0 IU/L) 4. This suggests that in the context of fatty liver disease, hydrochlorothiazide does not worsen hepatic function.
Clinical Approach
When evaluating elevated liver enzymes in a patient taking hydrochlorothiazide:
Consider alternative causes first: Drug-induced liver disease accounts for 10-50% of elevated enzymes in adults over 50, but hydrochlorothiazide is not among the commonly implicated agents (which include carbamazepine, methyldopa, minocycline, macrolides, nitrofurantoin, statins, sulfonamides, and methotrexate) 5, 6.
Look for temporal relationship: Onset of jaundice or enzyme elevation shortly after starting hydrochlorothiazide suggests causality 1.
Check for cholestatic pattern: Look for elevated alkaline phosphatase, GGT, and bilirubin alongside transaminases 2.
Rule out other causes: Exclude viral hepatitis, alcohol use, autoimmune hepatitis, biliary obstruction, and other hepatotoxic medications before attributing to hydrochlorothiazide 5.
Discontinue and monitor: If hydrochlorothiazide is suspected, stop the medication and monitor for improvement in liver tests over 2-4 weeks 1.
Bottom Line
While hydrochlorothiazide-induced hepatotoxicity is documented, it remains exceptionally rare. The medication should not be routinely avoided in patients with pre-existing liver enzyme elevations, as demonstrated by safety data in patients with fatty liver disease 4. However, if unexplained hepatocellular or cholestatic injury develops after initiating hydrochlorothiazide, consider it as a potential cause after excluding more common etiologies.